BIOAVAILABILITY AND SWALLOWABILITY OF AN AGE-APPROPRIATE, DELAYED-RELEASE MESALAMINE FORMULATION IN HEALTHY VOLUNTEERS

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers

Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for children with ulcerative colitis

read more